{"id":30436,"date":"2020-11-11T18:40:29","date_gmt":"2020-11-11T18:40:29","guid":{"rendered":"https:\/\/amelie-project.eu\/?post_type=press-release&p=30436"},"modified":"2021-05-08T07:38:26","modified_gmt":"2021-05-08T07:38:26","slug":"lue-sostiene-una-ricerca-innovativa-sullincontinenza-con-un-finanziamento-di-95-milioni-di-euro","status":"publish","type":"press-release","link":"https:\/\/amelie-project.eu\/it\/comunicato-stampa\/lue-sostiene-una-ricerca-innovativa-sullincontinenza-con-un-finanziamento-di-95-milioni-di-euro\/","title":{"rendered":"L'UE sostiene una ricerca innovativa sull'incontinenza con un finanziamento di 9,5 milioni di euro"},"content":{"rendered":"

[et_pb_section fb_built=”1″ _builder_version=”4.6.3″ custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_row _builder_version=”4.6.3″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” width=”100%” module_alignment=”center” custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”][et_pb_column type=”4_4″ _builder_version=”3.25″ custom_padding=”|||” custom_padding__hover=”|||”][et_pb_text _builder_version=”4.6.3″ text_font=”Gotham kinda bold||||||||” text_text_color=”#000000″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” custom_margin=”0px|0px|0px|0px|false|false” custom_padding=”0px|0px|0px|0px|false|false”]<\/p>\n

L'UE ha stanziato 9,5 milioni di euro per un progetto di ricerca innovativo sul trattamento dell'incontinenza fecale.<\/p>\n

L'obiettivo della ricerca \u00e8 quello di utilizzare una terapia cellulare rivoluzionaria per trovare una possibile cura per una patologia che, secondo le stime, colpisce 67 milioni di persone in Europa.<\/p>\n

Il finanziamento sar\u00e0 destinato a un consorzio di 13 organizzazioni di nove Paesi chiamato AMELIE (Anchored Muscle cELls for IncontinencE).<\/p>\n

Il progetto sar\u00e0 coordinato dall'UCL e guidato da Richard Day, professore di tecnologia della medicina rigenerativa all'UCL.<\/p>\n

Tra gli altri partner nel Regno Unito figurano la Queen Mary University of London, l'NHS Blood and Transplant e l'ente di beneficenza Bowel Research UK, che si occuper\u00e0 del coinvolgimento dei pazienti.<\/p>\n

La ricerca sar\u00e0 condotta nell'arco di cinque anni, con istituzioni diverse nel Regno Unito, in Spagna e in Portogallo che assumeranno il ruolo di guida in ogni nuova fase.<\/p>\n

Il progetto si concentra sul prelievo delle cellule muscolari del paziente, sul loro caricamento su microcarrier appositamente progettati e sull'impianto nel muscolo danneggiato per promuovere la rigenerazione e ripristinare la normale funzionalit\u00e0.<\/p>\n

Il professor Day ha affermato che questa terapia di medicina rigenerativa offre una speranza a molte persone la cui vita \u00e8 gravemente compromessa dall'incontinenza:<\/p>\n

\u201cSiamo estremamente entusiasti della prospettiva del progetto AMELIE e dei potenziali benefici che possono derivare dal nuovo approccio terapeutico che si sta studiando.<\/p>\n

\u201cNon vediamo l'ora di collaborare con l'eccezionale consorzio di accademici, medici, industrie e associazioni benefiche provenienti da tutta Europa per sviluppare il nostro approccio pionieristico alla medicina rigenerativa per il trattamento di questa patologia debilitante.<\/p>\n

\u201cSi tratter\u00e0 di un approccio radicale e innovativo, mai tentato prima d'ora su questa scala\u201d.\u201d<\/p>\n

Lesley Booth MBE, Direttore della Ricerca e dell'IPP del Bowel Research UK, ha dichiarato che, sebbene la condizione sia estremamente comune, non se ne parla molto.<\/p>\n

\u201cLa realt\u00e0 di vivere con l'incontinenza fecale pu\u00f2 essere devastante. \u00c8 sicuramente limitante per la vita. E il fatto che sia una condizione di cui non si parla liberamente non fa che aumentare le difficolt\u00e0 di condurre una vita normale\u201d.<\/p>\n

\u201cTrovare una terapia che funzioni non sarebbe solo una grande scoperta medica, ma cambierebbe la vita a milioni di persone\u201d.\u201d<\/p>\n

Questo progetto \u00e8 stato finanziato dal programma di ricerca e innovazione Horizon 2020 dell'Unione Europea con l'accordo di sovvenzione n. 874807.<\/p>\n

\n

<\/p>\n

[\/et_pb_text][et_pb_image src=”https:\/\/amelie-project.eu\/wp-content\/uploads\/2021\/01\/Picture-1.png” title_text=”Picture 1″ _builder_version=”4.6.3″ _module_preset=”default”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>","protected":false},"excerpt":{"rendered":"

The EU has awarded \u20ac9.5m to a ground breaking research project into the treatment of faecal incontinence. The aim of the research is to use revolutionary cell therapy to find a possible cure for a condition which affects an estimated 67 million people in Europe. The funding will go to a consortium of 13 organisations across nine countries called AMELIE (Anchored Muscle cELls for IncontinencE). The project will be co-ordinated by UCL and led by Richard Day, Professor of Regenerative Medicine Technology at UCL. Other partners in the UK include Queen Mary University of London, NHS Blood and Transplant and the charity Bowel Research UK, which will take the lead in patient involvement. The research will be conducted over five years, with separate institutions in the UK, Spain and Portugal taking the lead role at each new stage. The project will focus on taking the patient\u2019s own muscle cells, loading them onto specially designed microcarriers and implanting them into the damaged muscle to promote regeneration and restore normal function. Professor Day said that such regenerative medicine therapy offers hope to many people whose lives are severely impaired by incontinence: \u201cWe are tremendously excited by the prospect of the AMELIE project […]<\/p>","protected":false},"featured_media":31025,"template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"\n

The EU has awarded \u20ac9.5m to a ground breaking research project into the treatment of faecal incontinence.<\/p>\n\n\n\n

The aim of the research is to use revolutionary cell therapy to find a possible cure for a condition which affects an estimated 67 million people in Europe. <\/p>\n\n\n\n

The funding will go to a consortium of 13 organisations across nine countries called AMELIE (Anchored Muscle cELls for IncontinencE).<\/p>\n\n\n\n

The project will be co-ordinated by UCL and led by Richard Day, Professor of Regenerative Medicine Technology at UCL.<\/p>\n\n\n\n

Other partners in the UK include Queen Mary University of London, NHS Blood and Transplant and the charity Bowel Research UK, which will take the lead in patient involvement.<\/em><\/p>\n\n\n\n

The research will be conducted over five years, with separate institutions in the UK, Spain and Portugal taking the lead role at each new stage.<\/p>\n\n\n\n

The project will focus on taking the patient\u2019s own muscle cells, loading them onto specially designed microcarriers and implanting them into the damaged muscle to promote regeneration and restore normal function.<\/p>\n\n\n\n

Professor Day said that such regenerative medicine therapy offers hope to many people whose lives are severely impaired by incontinence:<\/p>\n\n\n\n

\u201cWe are tremendously excited by the prospect of the AMELIE project and the potential benefits that may arise from the new therapeutic approach being investigated.<\/p>\n\n\n\n

\u201cWe look forward to working with the exceptional consortium of academics, clinicians, industry and charity partners from across Europe to develop our pioneering regenerative medicine approach for treating this debilitating condition.<\/p>\n\n\n\n

\u201cThis will be a radical and innovative approach never before attempted at such a scale.\u201d<\/p>\n\n\n\n

Lesley Booth MBE, Director of Research and PPI at Bowel Research UK, said that, whilst the condition is extremely common, it is not much talked about.<\/p>\n\n\n\n

\u201cThe reality of living with faecal incontinence can be devastating. It is definitely life-limiting. And the fact that it\u2019s a condition which people don\u2019t discuss freely just adds to the difficulties of leading a normal life,\u201d she said.<\/p>\n\n\n\n

\u201cFinding a therapy which works would not just be a major medical breakthrough, it would be life-changing for millions.\u201d<\/p>\n\n\n\n

This project has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 874807.<\/p>\n\n\n\n

Ends<\/strong><\/p>\n\n\n\n

NOTES TO EDITORS<\/strong><\/p>\n\n\n\n

AMELIE<\/strong> (Anchored Muscle cELls for IncontinencE consortium) is made up of the following: University College London, Instituto Superior Tecnico (Portugal), Queen Mary University of London, Medical University of Graz (Austria), Aarhus University Hospital (Denmark), Rouen University Hospital (France), University Hospital Erlangen (Germany), Instituto de Investigacion Sanitaria Fundacion Jimenez Diaz (Spain), NHS Blood and Transplant (UK), Polysciences Europe GmbH (Germany), Ttopstart (Netherlands), Bowel Research (UK), Consorzio per Valutazioni Biologiche e Farmacologiche (Italy).<\/p>\n\n\n\n

Horizon 2020<\/strong> is an EU funding programme for research and innovation. It is the biggest EU Research and Innovation programme ever with nearly \u20ac80 billion of funding available over 7 years (2014 to 2020) \u2013 in addition to the private investment that this money will attract. It promises more breakthroughs, discoveries and world-firsts by taking great ideas from the lab to the market. https:\/\/ec.europa.eu\/programmes\/horizon2020\/en\/what-horizon-2020<\/a><\/p>\n\n\n\n

This project has received funding from the European Union\u2019s Horizon 2020 research and innovation programme under grant agreement No 874807.<\/p>\n\n\n\n

AMELIE contact:<\/strong><\/p>\n\n\n\n

Media contact:<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n","_et_gb_content_width":"","_coblocks_attr":"","_coblocks_dimensions":"","_coblocks_responsive_height":"","_coblocks_accordion_ie_support":"","_links_to":"","_links_to_target":""},"categories":[51],"class_list":["post-30436","press-release","type-press-release","status-publish","has-post-thumbnail","hentry","category-press-release"],"_links":{"self":[{"href":"https:\/\/amelie-project.eu\/it\/wp-json\/wp\/v2\/press-release\/30436","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/amelie-project.eu\/it\/wp-json\/wp\/v2\/press-release"}],"about":[{"href":"https:\/\/amelie-project.eu\/it\/wp-json\/wp\/v2\/types\/press-release"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/amelie-project.eu\/it\/wp-json\/wp\/v2\/media\/31025"}],"wp:attachment":[{"href":"https:\/\/amelie-project.eu\/it\/wp-json\/wp\/v2\/media?parent=30436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/amelie-project.eu\/it\/wp-json\/wp\/v2\/categories?post=30436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}